Insider · CIK 0001682017

Novak Rodger

Reports to the SEC for 1 company · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001682017

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2021-06-30	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−25K sh	$165.00	−$4.13M	573,007
2021-06-28	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−25K sh	$156.55	−$3.91M	598,007
2021-06-21	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−1,171 sh	$125.58	−$147K	646,836
2021-06-21	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−881 sh	$126.62	−$112K	645,955
2021-06-21	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−2,969 sh	$127.71	−$379K	642,986
2021-06-21	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−12.6K sh	$128.76	−$1.63M	630,356
2021-06-21	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−7,299 sh	$129.46	−$945K	623,057
2021-06-21	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−50 sh	$130.27	−$6,513.5	623,007
2020-11-30	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+50K sh	$14.00	+$700K	698,007
2020-11-30	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−50K sh	$125.00	−$6.25M	648,007
2020-11-30	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+50K sh	$14.43	+$722K	698,007
2020-11-30	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−50K sh	$125.00	−$6.25M	648,007
2020-11-30	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−50K sh	—	—	61,893
2020-11-30	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−50K sh	—	—	140,315
2020-10-09	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+2,762 sh	$14.43	+$39.9K	650,769
2020-10-09	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−2,762 sh	$100.00	−$276K	648,007
2020-10-09	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−2,762 sh	—	—	190,315
2020-10-08	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+22.2K sh	$14.43	+$321K	670,245
2020-10-08	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−22.2K sh	$100.00	−$2.22M	648,007
2020-10-08	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−22.2K sh	—	—	193,077
2020-09-01	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+3,933 sh	$14.00	+$55.1K	651,940
2020-09-01	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+21.1K sh	$14.43	+$304K	673,007
2020-09-01	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−1,406 sh	$91.54	−$129K	671,601
2020-09-01	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−19.8K sh	$92.59	−$1.83M	651,847
2020-09-01	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−3,840 sh	$93.19	−$358K	648,007
2020-09-01	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−3,933 sh	—	—	111,893
2020-09-01	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−21.1K sh	—	—	215,315
2020-08-19	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+25K sh	$14.00	+$350K	673,007
2020-08-19	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−25K sh	$100.00	−$2.5M	648,007
2020-08-19	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−25K sh	—	—	115,826
2020-07-07	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+5,586 sh	$1.81	+$10.1K	653,593
2020-07-07	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+19.4K sh	$14.00	+$272K	673,007
2020-07-07	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−25K sh	$90.00	−$2.25M	648,007
2020-07-07	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−5,586 sh	—	—	0
2020-07-07	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−19.4K sh	—	—	140,826
2020-07-01	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−50K sh	$80.00	−$4M	648,007
2020-06-23	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−50K sh	$75.00	−$3.75M	698,007
2020-05-26	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−36.6K sh	$70.27	−$2.57M	748,007
2020-05-22	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−13.4K sh	$70.01	−$937K	784,623
2020-05-19	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−50K sh	$65.00	−$3.25M	798,007
2019-11-19	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Director, President	MExercise/Conversion	+33.6K sh	$14.43	+$485K	33,618
2019-11-19	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−33.6K sh	$70.00	−$2.35M	0
2019-11-19	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Director, President	MExercise/Conversion	−33.6K sh	—	—	236,382
2019-07-10	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−50K sh	$50.00	−$2.5M	848,007
2019-06-10	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−50K sh	$45.00	−$2.25M	898,007
2019-03-04	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−64.1K sh	$40.24	−$2.58M	960,419
2019-03-04	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−8,912 sh	$41.29	−$368K	951,507
2019-03-04	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−3,500 sh	$42.03	−$147K	948,007
2019-03-01	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−8,693 sh	$40.01	−$348K	1,024,534
2019-02-25	CRSPCRISPR Therapeutics AGS Sale	Director, President	SSale	−14.8K sh	$40.00	−$591K	1,033,227

Recent filings

Accepted (ET)
Jul 14
Novak Rodger0001209191-21-044516
SEC(opens sec.gov)
Jun 304
Novak Rodger0001209191-21-044012
SEC(opens sec.gov)
Jun 234
Novak Rodger0001209191-21-042811
SEC(opens sec.gov)
Dec 24
Novak Rodger0001209191-20-061162
SEC(opens sec.gov)
Oct 134
Novak Rodger0001209191-20-054650
SEC(opens sec.gov)

Companies

CRISPR Therapeutics AGDirector, PresidentCRSP

Address

C/O CRISPR THERAPEUTICS, INC. 200 SIDNEY STREET

CAMBRIDGE, MA, 02139